UPF has obtained three of the sixteen grants awarded by ACC1Ó and cofunded by the European Union within the TECNIOSPRING technology transfer programme. In the field of biotechnology, all of the grants awarded have been to centres related with UPF.
Tomàs Marques-Bonet, ICREA researcher in the Department of Experimental and Health Sciences (CEXS) and head of the Comparative Genomics research group, which works on primates at the Institute of Evolutionary Biology (IBE), a UPF-CSIC joint centre, was invited by Salvador Moyà, director of the Miquel Crusafont Catalan Institute of Paleontology to give a lecture on Genetics and paleontology: in search of our origins" from 7.00 to 8.30 pm on 21 November, at the Bosch i Cardellach Foundation (C/ Indústria, 18, Sabadell).
This year, the TV3 Marathon Foundation has allocated more than 11 million euros from the 2012 Marathon to 42 research cancer projects. It is the most important investment in research that the Foundation has made in the programme's 21-year history.
A study conducted by the National Cancer Research Centre (CNIO), in which Tomàs Marques-Bonet, ICREA researcher at the Department of Experimental and Health Sciences (CEXS) and researcher at the IBE (UPF-CSIC) participated, has linked the late replication process with the evolution of life on Earth over millions of years for the first time.
The European Molecular Biology Organization (EMBO), an organization of 1,600 leading scientists that promotes excellence in the field of health and life sciences, has announced the twenty-three new researchers from the 2013 call who have joined the EMBO's network of young researchers and who will as a consequence receive funding 15,000 euros per year over the next three years to boost their research.
The theory of evolution formulated by Charles Darwin in the nineteenth century is certainly one of the scientific theories that has done most to transform our view of the world and of our own species. Today, Darwinism suggests that the evolution of the human species has both a cultural and a biological basis.
After months of negotiation, Pompeu Fabra University, represented by Francesc Posas, the Vice-rector for Science Policy, signed an exclusivity agreement on 7 October with Virbac, a French multinational company that is a leader in the animal health sector, to market a technology developed in the Department of Experimental and Health Sciences (CEXS). It is a veterinary vaccine for the prevention of foot and mouth disease, the most economically devastating animal disease worldwide.
Bladder cancer is a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded each year - one of the highest rates in the world. Most of these tumours have a good prognosis - 70-80% survival five years after diagnosis, and they do not infiltrate the bladder muscle at the time of diagnosis - in about 80% of cases.